A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

NCT03709121 PHASE1, PHASE2 COMPLETED Results posted

An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)

Details

Lead sponsor	Aldeyra Therapeutics, Inc.
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	70
Start date	Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Mar 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Conjunctivitis, Allergic

Interventions

• Reproxalap Ophthalmic Solution (0.25%)
• Reproxalap Ophthalmic Solution (0.5%)
• Vehicle Ophthalmic Solution

Countries

Canada